Learn more about whether Bausch + Lomb Corporation or UFP Technologies, Inc. is a better investment based on AAII's A+ ...

Bausch + Lomb announced today that, after engagement with potential buyers, it has no immediate plan to sell. At the end of 2024, the company issued a statement outlining its plans for a potential ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Learn more about whether Bausch + Lomb Corporation or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Detailed price information for Bausch Lomb Corporation (BLCO-T) from The Globe and Mail including charting and trades.

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) had its price objective lowered by stock analysts at Royal Bank of Canada from ...

In a report released today, Douglas Miehm from RBC Capital assigned a Buy rating to Bausch + Lomb Corporation (BLCO – Research Report), with a ...

“Surgeons around the world have long known the benefits of the enVista platform,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “In the U.S., where enVista Aspire is currently ...